Carcinoid Tumor: all 152 studies
Page 1 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsNot yet recruitingNCT07842172Phase 3
- Pharmaceutical Management in Targeted Radioligand TherapyRecruitingNCT07389512
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.RecruitingNCT07165132Phase 1
- ALG-LungCancerRegistry (SAFRO2202)RecruitingNCT07161882
- Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine TumorsRecruitingNCT06472388Phase 2
- Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic ImplicationsRecruitingNCT06321692Not applicable
- Genetics of Appendix Cancer StudyRecruitingNCT05734430
- Surgery With Extended (D3) Mesenterectomy for Small Bowel TumorsRecruitingNCT05670574Not applicable
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingNCT05263050Phase 2
- EMB-01 in Patients With Advanced/Metastatic Gastrointestinal CancersRecruitingNCT05176665Phase 1/2
- Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruitingNCT04907643Not applicable
- Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.RecruitingNCT04735198Not applicable
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingNCT04086485Phase 1/2
- RegisterNET - A Registry for Neuroendocrine Tumors in the USA and WorldwideEnrolling by invitationNCT02270567
- Natural History of Familial Carcinoid TumorRecruitingNCT00646022
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeCompletedNCT05361668Phase 2Results posted
- Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
- Bronchoscopic Laser Ablation of Peripheral Lung TumorsTerminatedNCT03707925Not applicableResults posted
- Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsTerminatedNCT03420521Phase 2Results posted
- Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELOCompletedNCT03223428Results posted
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresTerminatedNCT02859064Phase 2Results posted
- A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsCompletedNCT02795858Phase 2Results posted
- Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT02575300Phase 2Results posted
- YF476 and Type II Gastric CarcinoidsTerminatedNCT02454075Phase 2Results posted
- Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine TumorsCompletedNCT02441062Phase 2Results posted
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02399215Phase 2Results posted
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
- GA-68 DOTA-TOC of Somatostatin Positive MalignanciesTerminatedNCT02177773Phase 1/2Results posted
- Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3Results posted
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCompletedNCT02026063Phase 3Results posted
- P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid SyndromeTerminatedNCT01886287Phase 2Results posted
- Ziv-Aflibercept for Advanced Progressive Carcinoid TumorsCompletedNCT01782443Phase 2Results posted
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3Results posted
- Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid TumorsCompletedNCT01619865Phase 1/2Results posted
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedNCT01578239Phase 3Results posted
- Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsCompletedNCT01466036Phase 2Results posted
- A Study of Axitinib in Advanced Carcinoid TumorsCompletedNCT01435122Phase 2Results posted
- Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)CompletedNCT01327612Phase 2Results posted
- Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)CompletedNCT01253161Phase 2Results posted
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2Results posted
- AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT01024387Phase 2Results posted
- Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid SyndromeTerminatedNCT01018953Phase 2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsTerminatedNCT00947167Phase 2Results posted
- Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal CancerTerminatedNCT00903396Phase 2Results posted
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2Results posted
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeCompletedNCT00774930Phase 3Results posted
- Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine TumorsTerminatedNCT00730483Not applicableResults posted
- Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid DiseaseCompletedNCT00690430Phase 3Results posted
- RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in EuropeCompletedNCT00688623Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2Results posted
- Everolimus and Octreotide in Patients With Advanced Carcinoid TumorCompletedNCT00412061Phase 3Results posted
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsTerminatedNCT00227617Phase 2/3Results posted
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
- Study Evaluating SOM230 in Patients With Metastatic Carcinoid TumorsCompletedNCT00088595Phase 2Results posted
- Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022CompletedNCT07317726
- A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022CompletedNCT07317713
- The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022CompletedNCT07291752
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenActive, not recruitingNCT07087054Phase 3
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 2
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 3
- 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NETActive, not recruitingNCT05448157
- Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart DiseaseActive, not recruitingNCT05064514Not applicable
- Routine Transcervical Thymectomy in MEN-1 PatientsCompletedNCT05061784
- An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid TumorsActive, not recruitingNCT04993261Early Phase 1
- Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid LevelsWithdrawnNCT04931420Phase 2
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWithdrawnNCT04915144Phase 2
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylWithdrawnNCT04713202Phase 2
- Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine TumorsWithdrawnNCT04672876Phase 2
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerWithdrawnNCT04602117Phase 1
- Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation OptimisationTerminatedNCT04140409Phase 4
- Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family CaregiversWithdrawnNCT04085081Not applicable
- Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel FrequencyTerminatedNCT04073017Not applicable
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnNCT04065165Phase 3
- Carcinoid Heart Disease and Peptide Receptor Radiotargetted TherapyStatus unknownNCT04039516Phase 2
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingStatus unknownNCT04017104
- Active Surveillance in Early Lung CancerStatus unknownNCT03923777Not applicable
- Endoscopic Treatment of Bronchial Carcinoid TumorsCompletedNCT03723499
- Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETsCompletedNCT03722511Phase 2
- Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine CancersWithdrawnNCT03623984Early Phase 1
- Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)Status unknownNCT03622333Not applicable
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine TumorsActive, not recruitingNCT03498040
- Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainCompletedNCT03220087
- A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid TumorsWithdrawnNCT03057509Phase 1
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine TumorsCompletedNCT02826928Not applicable
- Personalized PRRT of Neuroendocrine TumorsActive, not recruitingNCT02754297Phase 2
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
- 18F-FDOPA PET in Neuroendocrine TumoursNo longer availableNCT02431715
- 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)TerminatedNCT02359500Phase 1
- 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine TumorsStatus unknownNCT02038738Phase 1/2
- 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive TumorsNo longer availableNCT01980732
- A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid TumorsStatus unknownNCT01731925Phase 2
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
- YF476 and Type I Gastric Carcinoids (Norway)TerminatedNCT01444014Phase 2
- Effects of Serotonin Excess on Bone in Carcinoid SyndromeCompletedNCT01430871